Cirrhosis, Hypertension, Laparoscopy, Splenectomy
Conditions
Keywords
Vagus nerve, Esophageal variceal re-bleeding, Cirrhosis, Hypertension, laparoscopy
Brief summary
This study aimed to evaluate whether synchronous vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation (SVEL) is effective and safe, and to determine whether SVEL can effectively decrease the incidence of postoperative esophageal variceal re-bleeding.
Detailed description
After successful screening the cases of cirrhosis of liver irrespective of the etiology who have prior esophageal/gastroesophageal variceal bleeding will be enrolled. The baseline parameter will be recorded and the patient will be randomized into either interventional (synchronous vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation (SVEL)) or control (single vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection without intraoperative endoscopic variceal ligation (SVEL)) group. From postoperative day 3, all patients will receive 100 mg oral aspirin enteric-coated tablets (Bayer, Leverkusen, Germany) once daily for 1 year, low-molecular-weight heparin (CS Bio, Hebei, China) subcutaneously (4.100 IU/day) for 5 days, and 25 mg of oral dipyridamole (Henan Furen, Henan, China) thrice daily for 3 months. At months 3, 6, and 12 after operation, endoscopic intervention will be done for all patients. Endoscopic variceal ligation was made if the diameter of the esophageal varices was \>5 mm. Postoperative complications of esophageal variceal re-bleeding and death due to re-bleeding will be recorded during the postoperative first year monitoring in the both groups as per the primary or secondary outcome.
Interventions
PROCEDURElaparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation
The modified procedure was implemented in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, divide the left lateral surface of the distal esophagus; (3) divide the posterior surface of the distal esophagus; (4) divide the anterior surface of the distal esophagus; (5) divide the lesser omental sac via the bottom right crural diaphragm; (6) transect en bloc the left gastric artery and vein and posterior gastric veins using a linear laparoscopic vascular stapler; (7) find the right crural diaphragm by dividing a small portion of the hepatogastric ligament at the left lateral esophagogastric junction; and (8) via the surface of the right crural diaphragm, divide the right lateral surface of the distal esophagus. After the procedure of laparoscopic azygoportal disconnection, intraoperative endoscopic variceal ligation was made if the diameter of the esophageal varices was \>5 mm.
Sponsors
Northern Jiangsu People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* A clinical, radiological or histologic diagnosis of cirrhosis of any etiology * Splenomegaly with secondary hypersplenism * esophageal/gastroesophageal variceal bleeding * No evidence of portal vein system thrombosis by ultrasound evaluation and angio-CT * Informed consent to participate in the study
Exclusion criteria
* Hepatocellular carcinoma or any other malignancy, * Hypercoagulable state other than the liver disease related * DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs. * Child - Pugh C * Recent peptic ulcer disease * History of Hemorrhagic stroke * Pregnancy * Uncontrolled Hypertension * Age\>75 yrs * Human immunodeficiency virus (HIV) infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Esophageal variceal re-bleeding | 1 year | Proportions of patients who will suffer from esophageal variceal re-bleeding |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Death due to re-bleeding | 1 year | Proportions of patients who will suffer from death due to re-bleeding |
| Overall survival | 1 year | Overall survival in both groups |
Countries
China
Outcome results
None listed